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,e objective of this study was to develop and validate a method for quantitative analysis of rivastigmine hydrogen tartrate (RHT)
in dual-ligand polymeric nanoparticle formulation matrices, drug release medium, and cellular transport medium. An isocratic
HPLC analysis method using a reverse phase C18 column and a simple mobile phase without buffer was developed, optimised, and
fully validated. Analyses were carried out at a flow rate of 1.5mL/min at 50°C and monitored at 214 nm. ,is HPLC method
exhibited good linearity, accuracy, and selectivity. ,e recovery (accuracy) of RHT from all matrices was greater than 99.2%. ,e
RHTpeak detected in the samples of a forced degradation study, drug loading study, release study, and cellular transport study was
pure and free of matrix interference. ,e limit of detection (LOD) and limit of quantification (LOQ) of the assay were 60 ng/mL
and 201 ng/mL, respectively. ,e method was rugged with good intra- and interday precision. ,is stability indicating HPLC
method was selective, accurate, and precise for analysing RHT loading and its stability in nanoparticle formulation, RHTrelease,
and cell transport medium.
1. Introduction
,ere is a worldwide increase in the prevalence of brain
diseases such as Alzheimer’s disease (AD), Parkinson’s
disease, and stroke due to the increase of the aging pop-
ulation. Consequently, there is an increase in demand for
effective treatments for these diseases. Rivastigmine hy-
drogen tartrate (RHT) was approved by the US FDA in 2000
for the treatment of mild-to-moderate dementia of either
Alzheimer’s type or related to Parkinson’s disease [1]. RHTis
a cholinesterase inhibitor that inhibits both acetylcholin-
esterase (AChE) and butyrylcholinesterase (BuChE) en-
zymes responsible for the degradation of acetylcholine
(ACh) into nonfunctional metabolites. Among the many
chemical changes that the brain encounters during AD,
depletion of ACh is one of the earliest and biggest changes.
RHT increases the central cholinergic function by enhancing
the ACh level in mild-to-moderate AD patients and inhibits
deposition of amyloid plaques in the brain, slowing down
the mental decline [2–6].
RHT has been reported to improve or maintain pa-
tients’ cognitive function, global function, behaviour, and
day-to-day activities [7, 8]. It is commercially available as
capsules, oral solution, and patches. However, the current
therapeutic regimen of RHTdemands frequent dosing, and
cholinergic side effects are common. Like other CNS drugs,
treatment efficacy of RHT is primarily restricted, not by the
drug’s inherent potency but by its ability to cross the blood-
brain barrier (BBB) into the brain due to its hydrophilic
nature [9].
To overcome the challenge of RHT transport into the
brain, it has been formulated into nanoparticles (NPs) since
2008 [9]. NPs act as a drug carrier to provide targeted
delivery of a concentrated payload to, and sustained release
at, the target site for therapeutic action. ,e targeting ability
of NPs is influenced by surface ligands that interact
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specifically at receptors on the target site. ,is targeting
approach is receiving increased attention for the develop-
ment of highly efficacious therapeutics with minimal side
effects that can be used in a wide range of diseases where
ideal pharmaceutical options are currently limited. Accurate
and efficient analytical methods that can facilitate the for-
mulation development and evaluation process are essential.
Our group recently developed dual-targeting ligand NPs for
the brain delivery of RHT [10, 11]. ,is was facilitated by the
development of an analytical method for quantitation of
RHT loading in a complex formulation and relevant cellular
and stability studies.
In the past, the quantitative determination of RHT has
been reported using several analytical techniques such as
spectrophotometry [12, 13], HPLC [14–17], gas
chromatography-mass spectrometry (GC-MS) [18–20], and
liquid chromatography-mass spectrometry (LC-MS) [21–
25]. For example, Fazil et al. [12] determined drug loading
and encapsulation efficiency by measuring the amount of
free RHT in the NPs supernatant using a UV spectropho-
tometer. ,e group used the same technique to quantify
RHT in phosphate-buffered saline (PBS) in their in
vitro permeability studies. Nagpal et al. [13] employed
spectrophotometry to measure drug loading, entrapment
efficiency, and RHT release from NPs in PBS. However,
spectrophotometry is not selective and cannot separate
formulation excipients, impurities, or degradation products
from the drug itself.
HPLC methods developed for RHT commonly employ
a buffer in the mobile phase and special columns, such as
Kromasil C8, XTerra RP18, and 5C18-MS, with either UV or
fluorescence detection for the analysis of RHT in different
samples [14–17, 26–29]. Table 1 summarises the HPLC
methods reported to date for separation and quantification
of RHT in different sample matrices.
Although HPLC coupled with mass spectrophotometry
(MS) is suitable or desirable for separation and quantifi-
cation of RHT in biological samples (rat, canine, and human
plasma, and rat brain and urine) [30], for initial formulation
development and evaluation, a fast, economic, and simple
yet selective and accurate HPLC method is preferred.
Furthermore, it is advantageous if the developed method is
also directly applicable for HPLC-MS analysis. ,erefore,
the objective of the current study was to develop and validate
a simple, fast, sensitive, selective, and accurate HPLC
method for the quantitative analysis of RHT loading in
Table 1: Summary of published HPLC conditions for RHT determinations.
Column Samplematrix Mobile phase Flow rate Detection technique
Analysis
time
Detection
limits Reference
Waters
Spherisorb
silica
Human
plasma
Acetonitrile-50mM
aqueous sodium
dihydrogen phosphate
(17 : 83 v/v, pH 3.1)
1.3mL/min UV: 200 nm 6minutes
LOD:
0.2 ng/mL [26]LOQ:
0.5 ng/mL
Inertsil
ODS-3V C18
Rat plasma
and brain
Ammonium acetate buffer
(20mM, pH 4.5) and
acetonitrile 74 : 26 (v/v)
1.0mL/min
Fluorescence detector,
Ex/Em wavelength:
220/293 nm
16
minutes
LOD: not
given [16]LOQ:
10 ng/mL
XTerra
RP18 C18
Raw material
10mM sodium-1-heptane
sulphonate (pH 3.0) and
acetonitrile 72 : 28 (v/v)
1.0mL/min UV: 217 nm 13minutes
LOD:
100 ng/mL [27]LOQ:
300 ng/mL
Monomeric C18 Rat plasma
Acetonitrile and
20mmol/L phosphate
buffer, pH 3.0 (25 : 75)
1.0mL/min
Fluorescence detector,
Ex/Em wavelength:
220/293 nm
20
minutes
LOD: not
given [28]LOQ:
25 ng/mL
5C18-MS Capsule
Methanol and water
(90 : 10) 1.0mL/min UV: 217 nm
Not
given
LOD: not
given [29]LOQ:
10.9 µg/mL
Kromasil C8 Liposomes
20mmol·L−1 phosphate
buffer (pH 3.0) and
acetonitrile (75 : 25%, v/v)
1.0mL/min UV: 210 nm 20minutes
LOD: not
given [17]LOQ:
10 ng/mL
C18
Solid lipid
nanoparticles
Acetonitrile and potassium
dihydrogen
orthophosphate buffer
(pH 6.0) (20 : 80 v/v)
1.0mL/min UV: 215 nm Notgiven
LOD: not
given [14]LOQ:
1 µg/mL
ODS C18 Liposomes
Acetonitrile : water
(20mM NaH2PO4·2H2O,
10mM Na2HPO4·12H2O)
(25 : 75, v/v)
1.0mL/min UV: 218 nm Notgiven
LOD: not
given [15]LOQ: not
given
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a dual-ligand NP formulation, its release and cellular
transport, and its stability profile under different stressed
conditions. Development criteria were that the chroma-
tography should be achieved on a commonly used C18
column and that the mobile phase was without a buffer, thus
allowing direct translation to HPLC-MS.
2. Experimental
RHT (purity ≥99.2%) was purchased from Innochem
Technology Co., Ltd. (Beijing, China). HPLC grade aceto-
nitrile (ACN) (purity ≥99.9%) was obtained from ,ermo
Fisher Scientific (Scoresby, Australia). Hanks’ balanced
salt solution (HBSS), 4-2-hydroxyethylpiperazine-1-
ethanesulfonic acid (HEPES) (purity≥ 99.5%), trifluoro-
acetic acid (TFA) (purity≥ 99.0%), and phosphate-buffered
saline (PBS) pouches were purchased from Sigma-Aldrich
(Castle Hill, Australia). D-glucose anhydrous, HCl (32%
w/v), and hydrogen peroxide (H2O2, 30%w/v) were ob-
tained fromAjax Finechem Pty Ltd. (Taren Point, Australia).
NaOH (purity≥ 98.0) was obtained from BDH Laboratory
Supplies (Poole, England). ,e transport buffer (HBSS-P)
was prepared from HBSS containing 10mM HEPES and
20mM glucose. Ultrapure (type 1) water was generated
using a Milli-Q System (Merck Millipore, Bayswater,
Australia).
2.1. Nanoparticle Preparation and Characterisation. ,e
dual-ligand PLGA-based NPs were prepared by a double
emulsion solvent evaporation technique [31–33]. RHT was
loaded in the NPs as a model drug.,e NPs formulation was
optimised to achieve optimum particle size for brain drug
delivery and maximal drug loading in the NPs. ,e opti-
mised NPs formulation was evaluated for in vitro charac-
teristics including particle morphology, size, zeta potential,
drug loading efficiency, release profile, and stability studies.
,e developed HPLC method was used for quantitative
analysis of RHT loading in the NPs formulation, release and
cellular transport, and stability profile under different
stressed conditions.
2.2.ChromatographicConditions. ,eHPLC system was an
Agilent® 1200 instrument (Agilent Technologies, Mul-
grave, Australia) with a degasser (G1379B), a binary pump
(G1312A), and an autosampler (G1329A) with thermo-
control unit (G1330B) and VWD (G1314B), Waters®
1122/WTC-120 external column heater (Waters Australia
Pty Ltd, Rydalmere, Australia), and a diode-array detector
(DAD, G1315B). Data acquisition and processing were
carried out with Agilent ChemStation® software version
B.04.03 SP1.
Samples were maintained at 4°C in the autosampler prior
to analysis. An Apollo C18 column, 5 µm particle size,
150mm× 4.6mm (Grace Davison Discovery Sciences,
Baulkham Hills, Australia), was maintained at 50°C. All
analyses were conducted with an isocratic mode with
a 1.5mL/min flow rate of the mobile phase (20% v/v ACN in
water containing 0.1% TFA, prefiltered through a 0.2 µm
hydrophilic nylon filter: MerckMillipore, Bayswater, Australia)
and injection volume of 50 µL. ,e detection of RHT was
monitored at an UV wavelength of 214 nm.
2.3. Forced Degradation Studies. Forced degradation studies
were conducted according to published protocols to confirm
the selectivity of the developed assay method [34–36]. RHT
(25 µg/mL) was used for all degradation studies. For acid
decomposition (hydrolysis) studies, RHT solution was
prepared in 2N HCl and incubated for 48 h at 37° and 60°C.
For base hydrolysis studies, RHT solution was prepared in
0.5NNaOH and incubated at 37°C and 60°C up to 48 h. Both
the acid and alkaline samples were cooled to RT and neu-
tralised before analysis by HPLC.
,e stability of RHT in water was assessed with RHT
solution (25 µg/mL) incubated at 37° and 60°C for 48 h,
whereas the effect of RHT oxidation was determined by
incubating RHT for 48 h at 37° and 60°C in 30% H2O2.
All degraded samples were analysed by HPLC, and RHT
peak purity was evaluated using a diode-array detector by
obtaining five UV spectra across the peak. ,e similarity
among these five spectra was determined and reported using
ChemStation software to determine the peak purity. Coe-
lution of any degraded product with the drug peak would
make the peak impure, resulting in dissimilar UV spectra.
,e software also reported whether the peak purity in each
spectrum was within the automatically set threshold limit.
2.4. Method Validation. ,e developed HPLC method was
validated with respect to selectivity, linearity, precision,
accuracy, limit of detection (LOD), and limit of quantifi-
cation (LOQ) in accordance with the International Council
for Harmonisation (ICH) Guidelines for Validation of An-
alytical Procedures, Q2B [37] and the United States Phar-
macopeia and the National Formulary (USP 37-NF 32) [38].
2.4.1. Selectivity. Forced degradation study samples were
used to assess the selectivity of the method. Supernatants of
both blank NPs (dual-ligand NPs without any loaded drug)
and RHT-loaded dual-ligand NPs were diluted 200 times in
the mobile phase and injected into the HPLC to study
whether any interfering peaks coeluted at or near the drug
peak. Similarly, the matrix interference was also investigated
using (i) PBS medium collected from release study control
(dual-ligand NPs without any loaded drug) and (ii)
uptake/transport study buffer (HBSS-P) comprising HBSS
containing 10mM HEPES and 20mM glucose (collectively
the “experimental media”).
2.4.2. Linearity. ,e linearity of the developed assay method
was assessed in two different media: 0.3% vitamin E-TPGS
(solvent for dispersion of dual-ligand nanoparticle) and PBS
(release study medium). A range of concentrations of RHT
solutions (0.1 to 2mg/mL) was prepared in 0.3% vitamin
E-TPGS from a stock solution (2mg/mL RHT in 0.3% vi-
tamin E-TPGS). Each solution was then diluted 200 times
(50 µL into 10mL) with the mobile phase to obtain the final
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RHTstandard concentrations of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
10 µg/mL. ,ese standards were injected into the HPLC
column, in duplicate. Another set of standards with the same
concentration range was prepared by diluting an RHT stock
solution (1mg/mL) in type 1 water with 10mM PBS (pH 7.4).
Again, these standards were injected into the HPLC column
in duplicate. Average peak area data were plotted against
corresponding standard concentrations using Microsoft®
Excel 2016 to construct the standard calibration curve. ,e
linearity was established by calculating the R2 value.
2.4.3. Precision. ,e precision of the proposed method was
determined by injecting four RHT concentrations (1, 4, 6,
and 10 µg/mL) in the experimental media, six times into
the HPLC. ,e relative standard deviation (RSD) values
were calculated for all concentrations.
2.4.4. Limit of Detection (LOD). ,e LOD was determined
as the drug concentration that produced a signal three times
greater than the baseline noise level. Two blank solvents,
namely, (1) 0.3% vitamin E-TPGS diluted 200 times in the
mobile phase and (2) 10mM PBS, pH 7.4, were injected six
times to determine the average noise levels. Standard RHT
solutions prepared in the mobile phase were analysed and
calibration curves constructed by plotting average peak
heights against the corresponding concentrations. ,e LOD
was calculated by the following formula:
LOD � 3 ×
Peak height of noise
Slope of calibration curve constructed by peak height versus conc
.
(1)
2.4.5. Limit of Quantification (LOQ). Using the same data,
the LOQ was determined as the concentration with the
signal at ten times greater than the baseline noise level. ,e
LOQ was calculated by the following formula:
LOQ � 10 ×
Peak height of noise
Slope of curve constructed by peak height versus conc
. (2)
2.4.6. Intra- and Interday Repeatability (Ruggedness). ,ree
standard concentrations of RHT (low, medium, and high) in
each solvent (0.3% vitamin E-TPGS diluted 200 times in the
mobile phase and 10mM PBS, pH 7.4) within the calibration
curve were selected. ,e intra- and interday repeatability of
the method was assessed by analysing these 1, 5, and 10 µg/mL
RHT standards, in triplicate, at different time points in the
same day and on two different days. In addition, the rug-
gedness study was conducted by analysing another set of RHT
standards of the same concentrations by a second analyst on
a different day. ,e RSD was calculated for each analysed
concentration and compared with the nominal limit to
evaluate the intra- and interday repeatability of the method
and ruggedness.
2.4.7. Accuracy. ,e accuracy of the developed method was
determined in two media to assess the interference of the
dual-ligand NPs formulation matrices and solvents. Firstly,
a batch of drug-free dual-ligand NPs (blank NPs) was
prepared, and the supernatant was collected during the last
step of the preparation. ,e supernatant was then spiked
with RHT to obtain a solution of RHT (2mg/mL).,is stock
solution was diluted with the same supernatant medium to
prepare five RHT solutions with concentrations of 0.1, 0.4,
0.8, 1.2, and 1.6mg/mL. ,ese solutions were diluted 200
times with the mobile phase to obtain the final drug con-
centrations of 0.5, 2, 4, 6, 8, and 10 µg/mL and injected into
the HPLC column in triplicate. ,is procedure mimics the
method of sample preparation for the determination of RHT
loading in dual-ligand NPs.
Secondly, an in vitro release study of the blank dual-
ligand NPs was carried out at pH 7.4 in PBS (mimicking the
NPmatrix in the release medium). 3mL of blank dual-ligand
NPs suspension was loaded in a dialysis tube (MWCO
12000), sealed, and placed in a 60 g amber glass jar con-
taining 50mL prewarmed PBS at 37°C. ,e setup was placed
on an orbital shaker at 37°C and horizontally shaken at
100 rpm. Release medium from outside the dialysis bag was
collected after 24 h, spiked with RHT standard solution
(200 µg/mL) prepared in type 1 water to get the final RHT
concentrations of 2, 4, 6, 8, and 10 µg/mL, and injected into
the HPLC column in triplicate. ,e concentration of RHT in
all samples was determined against RHTstandards prepared
in the mobile phase.
,e method accuracy was determined by calculating the
percentage of recovery (measured concentration over the
added concentration) in each case.
3. Results and Discussion
,e NP formulation was optimised to achieve the particle
size between 70 nm and 200 nm as well as to achieve the
highest possible drug loading in the NPs. ,e optimised
RHT-loaded dual-ligand NPs were found to have negative
zeta potential (−24.3± 2.5mV) and narrow size distribution
(139.5± 3.9 nm) ideal for targeting the BBB.
3.1. Development and Optimisation of HPLC Method. ,e
HPLC method for separation and quantification of RHT in
PBS (pH 7.4) and NP supernatant (containing 0.3% vitamin
E-TPGS) was developed and validated. An appropriate
combination of the column type, column temperature, mobile
phase composition and flow rate, injection volume, and
detection system was studied to produce a simple, fast,
economic, and yet selective and accurate assay method. We
validated 50 µL injection volume as the maximum injection
volume for future application in analysis of biological sam-
ples. ,e UV wavelength of 214 nm was selected for the
detection of the compound based on the UV spectrum of
RHT. A lower wavelength (209 nm) produced a much
stronger drug signal, but higher background noise made this
approach impractical. ,e mobile phase composition was
developed based on the solubility and pKa of RHT (8.85) [39].
An acidic condition (pH 2.6) was considered necessary
to keep all RHT molecules ionised (Figure 1). At this lower
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pH, the silane groups of the C18 column were also fully
protonated, leading to weak interaction with RHT, thereby
shortening the elution time. TFA was used to provide a good
peak shape and avoid the use of buer salts that may pre-
cipitate due to an interaction with formulation excipients. In
addition, eliminating a buer allows the method to be easily
adapted for LC-MS analysis of RHT in the future. e initial
trial mobile phase composed of ACN and water (50 : 50 v/v)
containing 0.1%TFA at a ow rate of 1mL/min resulted in the
RHTeluting with the solvent front. Consequently, the organic
phase was optimised at a ratio of 20 : 80 (v/v) for ACN : water
to produce the best peak shape and separation. e ow rate
was increased to 1.5mL/min, and column temperature was
maintained at 50°C to facilitate separation, sharpen the peaks,
and reduce the retention time to 6.8min. Mullangi et al. [16]
also employed a similar mobile phase composed of ACN and
water (26 : 74 v/v) and acidic pH of 4.5 for the analysis of
RHT. However, our developed method utilises a less-
expensive shorter column and a shorter run time, thereby
providing economic benets.
3.2. ForcedDegradationofRHTandSelectivity. emain aim
of the forced degradation studies of RHT was to assess the
selectivity of the analytical method. According to the MSDS
supplied by the manufacturer, RHT is chemically stable
under normal conditions but incompatible with strong
acids, bases, and oxidising agents. No light sensitivity data
were provided in the MSDS; however, RHT was reported to
be stable when exposed to light for at least ten days [27]. In
our investigation, various stress conditions were employed
to simulate any possible degradation that might occur
during the NPs preparation and in vitro characterisation
experiments. RHT was subjected to hydrolysis (acidic, al-
kaline, and neutral pH) and oxidation. Our results (Table 2)
showed a similar degradation pattern for RHT as per the
published literature [27]. We found that RHT was most
prone to base degradation, showing maximum degradation
after 48 h incubation at 37°C, compared to acidic, oxidative,
and hydrolysis in water conditions. e drug demonstrated
excellent stability against hydrolysis conditions at neutral
pH under both test temperatures, but oxidised easily at 37°C,
with complete degradation after 48 h incubation at 60°C.
RHT stability in 2N HCl was relatively good with 2.2%
degradation at 37°C over 48 h.
Figure 2 illustrates that our developed HPLC assay
method is capable of separating RHT from all degradation
products and that the RHTpeak obtained at 6.8min is pure.
Peak purity analysis was conducted using the default settings
of the ChemStation software without any manual data entry.
e peak purity of degraded products was not checked
because we were only interested in assessing the method’s
capability of resolving the pure RHT peak. e eluted RHT
peak was well separated from the degraded products (re-
tention time< 6min). us, the developed method was
selective and can be used as a stability indicating method for
the analysis of RHT concentration in various samples in-
cluding stability samples.
As our RHT samples of interest are from dual-ligand
nanoparticle formulation, release, and cellular transport
studies, it is important that the matrices present in those
samples do not interfere with the RHT quantitation.
erefore, further selectivity studies were carried out to
conrm that the developed HPLC method has the capa-
bility to generate “true results” that are free from matrix or
medium interference. e HPLC spectra in Figure 3 in-
dicate that there was no peak around the RHT retention
time (6.8–6.9min) in any of the experimental media: (i)
supernatant of dual-ligand NPs without any loaded drug
(after 200 times dilution with the mobile phase), (ii) PBS
medium following release study of empty dual-ligand NPs,
and (iii) cellular transport study medium (HBSS-P). is
NH N 
N N 
pKa = 8.85
HH
O
O
O
O
+
CH3
CH3
CH3
CH3
CH3 CH3
CH3
CH3
CH3
CH3
Figure 1: Ionisation of rivastigmine tartrate.
Table 2: Summary of ndings in RHT-forced degradation studies.
Forced degradation condition Temp. (°C) Incubation duration (hrs) Remaining percentage
Acid hydrolysis: RHT in 2N HCl 60 48 87.437 48 97.8
Base hydrolysis: RHT in 0.5N NaOH
60 2 80.9
60 48 0.0
37 48 29.7
Hydrolysis: RHT in water 60 48 99.237 48 99.7
Oxidation: RHT in 30% (w/v) H2O2
60 48 0.0
37 48 79.6
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demonstrates that there was no matrix interference and the
method is selective or specic for analysis of RHT under
various conditions.
3.3. Linearity. e detector response to various concen-
trations of RHT in two media produced a linear relationship.
For 50 µL injections of RHT in vitamin E-TPGS (following
200 times dilution with the mobile phase), the regression
plot demonstrated a nearly perfect linear relationship (co-
e©cient of variance was 0.9999) over the concentration
range of 0.5–10 µg/mL that covered the concentrations en-
countered in the RHT loading analysis. e same concen-
tration range of RHT in PBS also demonstrated a good linear
relationship with a coe©cient of variance of 0.9998.
3.4. Precision. e precision study was also conducted with
the three media used in the selectivity study (Table 3). All
RSD values were well below the nominally acceptable level of≤2% [40]. Even at the low concentrations of RHT (1μg/mL),
the RSD of 1.04–1.28% was achieved, demonstrating that the
method is precise.
3.5. LOD and LOQ. e LOD of an analytical procedure is
the lowest detectable amount of an analyte in a sample but
not necessarily a quantiable value. For the current method,
the lowest detectable concentration of RHT in both solvent
systems was 60 ng/mL.
e LOQ is the lowest amount of the drug in the sample
that can be condently quantied using the method. For the
current method, the lowest quantiable concentration of
RHT in both solvent systems was 201 ng/mL. e LOD and
LOQ is in a comparable range or even better than other
published methods [14, 27], and this method can also meet
the analytical requirements of dual-ligand NP formulation
development and evaluation.
3.6. Intra- and Interday Repeatability. e intra- and
interday repeatability data are shown in Table 4. All RSD
values of repeated analysis were within the acceptable limit
of ≤2% [40]. e ruggedness study performed by dierent
analysts also demonstrated similar trend with RSD values
below 2% (data not shown). ese results suggest that the
developed method is rugged.
3.7. Accuracy. e accuracy of a method demonstrates
that the assay can accurately quantify the molecule(s)
of interest in the presence of other possible interfering
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
(min)6.6 6.8 7 7.2
Calculated
(a)
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
(min)6.6 6.8 7 7.2
Calculated
(b)
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
(min)6.6 6.8 7 7.2
Calculated
(c)
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
(min)6.6 6.8 7 7.2
Calculated
(d)
Figure 2: HPLC chromatogram of RHT under various stress conditions conducted at 37°C for 48 hours. (a) Acid degradation, (b) alkali
degradation, (c) hydrolysis, and (d) oxidation. Analysis of RHTwas not interfered by the degradation products (∗). Peak purity reports are
shown in the insets, conrming that the RHT peaks are pure and the purity factors are within the calculated threshold limit.
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components such as excipients, reactions components,
release medium, and cellular transport medium. ,e ac-
curacy of the proposed method was calculated as per-
centage recovery from the six concentrations covering the
entire RHT concentration range within the calibration
curve. RHT was successfully recovered from all samples
in three experimental media (Table 5) with an accuracy
of 99.5 ± 1%, which is within the acceptable range [40].
,is suggests that none of the matrices in the dual-ligand
nanoparticle formulation or medium/buffer is interfering
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
4.
29
1
(a)
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
4.
29
3
6.
86
9
(b)
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
(c)
(min)0 2 4 6 8
(mAU)
0
20
40
60
80
6.
87
6
(d)
(min)0 2 4 6 8
(mAU)
–2
0
2
4
6
8
10
(e)
(min)0 2 4 6 8
(mAU)
–2
0
2
4
6
8
10 6.
87
1
(f)
Figure 3: HPLC chromatograms illustrating absence of any matrix interfering peak around the RHT retention time (6.9 minutes).
Chromatograms of (a) empty dual-ligand NPs matrix, (b) RHT-loaded dual-ligand NPs matrix, (c) release medium after 24-hour release
study of empty dual-ligand NPs, (d) release medium after 24-hour release study of RHT-loaded dual-ligand NPs, (e) cell transport medium,
and (f) released RHT from NPs in cell transport medium after the transport study.
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with the assay of RHT. It can be concluded that the de-
veloped HPLC assay method can be used to produce ac-
curate data.
4. Conclusion
To assist the development of dual-ligand NP formulations
for brain drug delivery, we have developed a simple, fast,
accurate, and reliable HPLCmethod for RHTanalysis during
the formulation development and evaluation. ,is HPLC
method has been validated for analysis of RHT loading in
dual-ligand NPs preparations, in vitro drug release, and
cellular transport studies. ,e chromatographic separation
was achieved using a C18 column maintained at 50°C and an
isocratic mobile phase consisting of TFA containing ACN
and water with a flow rate of 1.5mL/min. ,e method
exhibited good linearity over the assayed concentration
range and good intra- and interday precision.,e developed
HPLC method is accurate, selective, and rugged for RHT
analysis with good detection and quantification limits and is
suitable for its intended use. ,is stability indicating ana-
lytical method can be adapted easily to analyse RHT in
pharmaceutical formulations and biological matrices and for
the future use in HPLC-MS analysis.
Conflicts of Interest
,e authors declare that there are no conflicts of interest
regarding the publication of this article.
Acknowledgments
,e authors wish to thank Dr. Andrew Crowe, Mr. Giuseppe
Luna, Mr. Michael Boddy, Ms. Yan-Jing Ng, andMs. Yeakuty
Marzan Jhanker for their technical assistance. Naz Hasan
Huda and Bhawna Gauri wish to acknowledge the support of
Curtin Strategic International Research Scholarship (CSIRS).
Table 3: ,e precision of the HPLC method for determination of RHT.
RHT conc.
(µg/mL)
RHT in NPs matrix RHT in release medium RHT in cell transport medium
Average RHT peak area
(mAU× sec)
RSD
(%)
Average RHT peak area
(mAU× sec)
RSD
(%)
Average RHT peak area
(mAU× sec)
RSD
(%)
1 36.50 1.04 36.22 1.28 36.02 1.06
4 145.97 0.59 145.82 0.67 144.24 0.66
6 219.73 0.49 220.98 0.28 218.64 0.48
10 370.20 0.17 369.30 0.19 369.15 0.23
Table 4: Intra- and interday repeatability of RHT analysis in NPs matrix, release medium, and cell transport medium.
RHT concentrationa
(µg/mL)
RHT in NPs matrix (200x diluted
in mobile phase) RHT in release medium RHT in cell transport medium
Intraday RSDb Interday RSDc Intraday RSDb Interday RSDc Intraday RSDb Interday RSDc
1 0.69 1.32 0.73 0.64 0.94 1.24
5 0.92 0.92 0.65 1.11 0.51 1.11
10 0.49 1.19 0.35 1.02 0.15 0.95
aEach concentration was analysed in triplicate (n � 3); bthe analyses were carried out at 0, 3, and 8 hrs on the same day, and all data were included in the
calculation; cthe analyses were carried out at days 1 and 2, and all data were included in the calculation.
Table 5: Accuracy data for RHT in NPs matrix, release medium, and cell transport medium.
Prepared RHT
concentration (µg/mL)
RHT in NPs matrix RHT in release medium RHT in cell transport medium
Measured
concentration (µg/mL)
Recovery
(%)
Measured
concentration (µg/mL)
Recovery
(%)
Measured
concentration (µg/mL)
Recovery
(%)
0.50 0.49± 0.13 98.0± 0.2 0.49± 0.11 98.4± 0.1 0.49± 0.16 98.6± 0.2
2.00 1.99± 0.16 99.5± 0.3 2.01± 0.10 100.5±0.3 2.00± 0.12 99.8± 0.2
4.00 3.96± 0.19 99.0± 0.3 4.04± 0.24 101.0±0.2 3.95± 0.31 98.7± 0.3
6.00 5.97± 0.11 99.5± 0.1 5.95± 0.25 99.2± 0.2 5.93± 0.15 98.8± 0.2
8.00 8.03± 0.16 100.4±0.3 7.98± 0.19 99.8± 0.6 7.97± 0.16 99.6± 0.2
10.00 9.99± 0.37 99.9± 0.2 9.99± 0.15 99.9± 0.2 9.98± 0.24 99.8± 0.1
Mean± SD� 99.4± 0.8 Mean± SD� 99.8± 0.9 Mean± SD� 99.2± 0.9
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